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Cardiovascular disease causes many lasting heart problems because when blood 
flow is blocked to an area of the heart, the cells in that area are damaged and could die.  
This dead area causes increased strain on the rest of the heart because the cells are unable 
to repair themselves.  Human pluripotent stem cells have the ability to differentiate into 
the muscle cells of the heart, cardiomyocytes, which could be useful in treating the 
damaged areas of the heart.  Currently, differentiation processes result in low yields of 
cardiomyocytes that additionally have an immature phenotype.  Before these processes 
can be clinically relevant, the yield of cardiomyocytes must be improved.  In original 
studies, it has been shown that 3D cardiospheres, or aggregated cardiomyocytes, enriched 
the cardiomyocyte populations and resulted in more mature cells compared to the 2D 
controls1.  This study expands on the formation of cardiospheres by aggregating them at 
different time points during the protocol.  Initial data was collected regarding the number 
of cells/well of the differentiation cultures, number of cells seeded per cardiosphere, and 
beating frequency for the cardiospheres made on Day -4 Day 0, Day 5, Day 9, and Day 
14.  This study proved it is possible to form beating cardiomyocytes at earlier time points 
in the differentiation.  The size of the cardiospheres was variable between time points, 






Heart disease is responsible for 1 in every 4 deaths for both men and women in 
America, killing about 600,000 people annually2.  The heart has little endogenous ability 
to repair itself, but stem cells have the potential to be used as therapeutics for the repair of 
damaged hearts.  Human pluripotent stem cells (hPSCs) have the ability to differentiate 
into the muscle cells of the heart, cardiomyocytes (hPSC-CM), which could be useful in 
tissue engineering and cell-based therapies for damaged myocardium.  Studies have 
demonstrated the ability to generate populations of cardiomyocytes by treating human 
pluripotent stem cells with growth factors such as Activin A and BMP43, using 
supporting extracellular matrices4, or using small molecule directed protocols5 in an 
attempt to achieve enriched, homogeneous cardiac differentiation.  Further, hPSC-CMs 
have been used in tissue engineering approaches, such as forming a “biowire” out of the 
cells to use as a suture in the heart6.  However, one current limitation with current 
differentiation protocols is that hPSC-CM efficiency is highly variable, illustrating a need 
for improvement.  Additionally, the hPSC-CM yields an immature phenotype resembling 
that of embryonic hPSC-CM, not mature adult hPSC-CM.  In order for cell-based cardiac 
therapies to realize their clinical potential, methods to enrich and mature the hPSC-CM 
populations are required.   
 In our previous work, we generated 3D cardiospheres from pre-differentiated 
hPSC-CM derived from human pluripotent stem cells. The formation of these 3D 
cardiospheres has enriched the hPSC-CM populations and resulted in early signs of a 
more mature cardiomyocyte phenotype compared to 2D controls1.  The goal of this 
project is to identify at what stage during the pre-differentiation process we are able to 
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create cardiospheres with the highest yield of mature hPSC-CM in an attempt to create a 






There are many hurdles to jump before cardiomyocytes can become clinically 
relevant.  The hPSCs need to differentiate with a high yield of cardiomyocytes, the 
maturation age of the cardiomyocytes and the methods for implantation needs to be 
optimized for transplant, and lasting effects of the implantation need to be characterized. 
 
Previous Studies 
Studies have demonstrated the ability to generate populations of cardiomyocytes 
by treating the cells with activin A and BMP43, using extracellular matrices on either side 
of the pluripotent cells4  (matrigel sandwich), or using small molecule directed protocols7 
in an attempt to encourage more pure cardiac differentiation.  In this aspect, the three 
different protocols had purity yields of 82.6%3, 40%-92%4, and 80%-98%7 respectively.  
These percentages are too low or too wide of a range to produce efficient, dependable 
results, although the last protocol shows the most promise as an initial study to be 
expanded upon.  In addition, all these protocols require a significant amount of time to 
produce the cardiomyocytes, making it harder to complete follow up studies in an 
expedited fashion.  
 Little is known regarding the maturation of the implanted cardiomyocytes in the 
mouse models.  Purely embroyd-body (EB) derived transplants had only an 18% success 
in injured mouse heart grafts3 when compared to a 90% success in uninjured mouse heart 
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grafts.  All the hearts that contained the surviving EB grafts also displayed “a substantial 
component of noncardiac elements, including rare epithelium-lined cysts3.”  This poses a 
problem with regards to heart transplants because data must show a complete lack of 
teratomas, cysts, and anything not cardiac specific in order to be safe and applicable to 
human implants.  This study then focused on changing the mechanics behind the graft 
implementation1 in an attempt to prevent cardiomyocyte death after transplant.  Another 
possible way to increase graft success is to increase the purity of the cardiomyocytes 
before implantation.  This would lead to less noncardiac elements, implying a safer and 
more successful graft.   
A different study formed a biowire out of cardiomyocytes to use as a suture in the 
heart6.  Their EBs showed low levels of maturation, even when taken out to day 406.  The 
study hoped that by physically organizing the hPSCs spatially in a way that represented 
how the hPSCs would be organized in the heart, the cells would mature faster.  After two 
weeks in culture, the cardiomyocytes on the biowire closely resembled adult 
cardiomyocytes6.  This study provides a novel way to mature the cardiomyocytes and 
force them to have a more cardiac muscle-like appearance.  While they did not implant 
these biowires in this study, it is highly plausible that the more mature cardiomyocytes 
would better integrate into the existing heart muscle. 
Therefore, one current limitation with cardiomyocyte is that cardiomyocyte 
efficiency resulting from differentiation protocols is highly variable, and the purification 
needs improvement.  Additionally, the cardiomyocyte yield an immature phenotype 
resembling that of embryonic cardiomyocyte, not mature adult cardiomyocyte.  In order 
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for cell-based cardiac therapies to realize their clinical potential, methods to enrich and 
mature the cardiomyocyte populations are required.   
 
Cardiospheres 
In original studies, 3D cardiospheres, similar to EBs, have been generated from 
pre-differentiated cardiomyocytes derived from human pluripotent stem cells. The 
formation of these 3D cardiospheres has enriched the cardiomyocyte populations and 
resulted in more mature cells compared to the 2D controls1.  Almost 100% of the 
cardiospheres showed spontaneous contraction, even when the 2D populations started 
with about 10%-40% cardiomyocytes1.  These cardiospheres even had enhanced 
structural maturation when compared with the 2D controls1.  This work shows that 
generating cardiomyocytes in a three dimensional way holds promise to mature the cells 
faster at a higher purity.  Moving forward, this differentiation process should be further 





MATERIALS AND METHODS 
 
 The overall objective of these studies is to evaluate the cardiac differentiation 
process by forming aggregates at four different time points during the differentiation  
process.  These four 
time points are 
illustrated in Figure 
1, where the cells 
differentiate from 
pluripotent cells 
into hPSC-CM.  
The first time point 
 
Figure 1- Overview of Experimental Design 
corresponds to the initial seeding of the hPSCs for the experiment, before pluripotent 
culture (D-4).  The second time point is prior to differentiation when the cells are still 
pluripotent (D0).  The third time point is after directed mesoderm differentiation via 
modulation of the Wnt signaling pathway (D5).  The fourth time point was chosen at the 
day spontaneous beating is first observed during the differentiation process (D9).  The 
final time point is when the cells show robust beating (D14). At each of these time points 
3D aggregates will be formed as shown in Figure 2 and will continue to be cultured for 
up to a total of 21 days before being evaluated. 
The differentiation process for the hPSCs was followed using a previously 
established protocol1.  In preliminary studies, seeding the hPSCs in 12-well plates at 
200,000 cells/well optimized the protocol. The cells were cultured for three days with 
daily mTeSR medium changes until they reached confluence. Cardiac differentiation was 
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directed with the GsK3 inhibitor and Wnt inhibitor1.  The small molecules modulated the 
Wnt signaling pathway over the course of the first 5 days of differentiation.  Between 
days 7-9, small 
beating foci were 
observed in 
regions of the 
wells.  By day 14 
of differentiation, 
 
Figure 2- Process of Cardiosphere Generation 
robustly beating cells were observed across all culture wells.  Cells were used at different 
points in this differentiation timeline (D-4, D0, D5, D9, D14) to form cardiospheres.  
Cardiospheres were formed by trypsinizing cardiomyocytes into single-cell suspension, 
resuspending the cells at a concentration of 1500 cells/aggregate, and centrifuging the 
cells into Aggrewell inserts filled with 400um microwells (Figure 2).  After 24 hours, the 
cardiospheres were removed from the wells and transferred to rotary culture.  The 
cardiomyocytes remained in rotary culture until day 21 of the protocol. 
 To assess the phenotype of the resulting hPSC-CM, we will utilize a variety of 
quantitative assays.  To quantify the percentage of hPSC-CM in the cardiospheres 
generated at the different time points, flow cytometry will be used on cells stained for α-
actinin. To evaluate the distribution of hPSC-CM within the cardiospheres, wholemount 
immunostaining for α-actinin combined with confocal microscopy will be used.  
Cardiospheres will be dissociated, replated, and stained for further immunostaining with 
both progenitor (nkx2.5) and mature (Troponin T, Connexin43) hPSC-CM markers to 
determine the maturity levels of the cardiospheres by staining.  If differences are 
observed in the percentages or the maturity level of the cells from different treatment 








Initial data was collected 
regarding the number of cells/well 
of the differentiation cultures, 
number of cells seeded per 
cardiosphere, and beating 
frequency was recorded for the 
cardiospheres made on Day -4 
Day 0, Day 5, Day 9, and Day 14. 
 
Figure 3-Cell Numbers Throughout Differentiation 
Process.  Throughout the differentiaton protocol, cells 
proliferate while they differentiate. 
 
The first cardiospheres were formed on Day -4 (group 1), which is the same day 
the rest of the hPSCs were seeded in the 12 well plates.  Forming cardiospheres on Day -
1 (group 2) instead of Day 0 ensures that the small molecule was not added during the 
aggregation process, but one day after instead.  At Day 0 cell counts were performed to 
determine that there were 56,600 cells/cm2 in the wells.  The cardiospheres were formed 
in five 24 well Aggrewell inserts, making the total aggregate concentration 6000 
cardiospheres per plate. No beating was recorded in any aggregates at this time point.  
Similarly, cardiospheres were produced on Day 5 (group 3) of the protocol.  The 
concentration of the cells at this point was 167,000-cells/ cm2 in each well.  Group 3 
formed cardiospheres smaller than those formed in groups 1 and 2.  Beating was 
observed on Day 17 in some of the aggregates, primarily in the smaller cardiospheres.  
Cardiospheres created on Day 9 (group 4) of the protocol contained a cell concentration  
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of 474,000-
cells/ cm2 in 
each well.  
These 
cardiospheres 





groups 1 and 2. 
 
Figure 4- Cardiospheres Formed at Different Time Points.  Images show 
phenotypes of cardiosphere formation throughout the differentiation proces.  Groups 
1 and 2 produce larger cardiospheres. 
 Finally, cardiomyocytes formed at Day 14 (group 5) had grown to a cell density 
of 293,000-cells/ cm2 in each well.  These cardiospheres were also much smaller than the 






 In conclusion, this study showed that it is possible to form beating 
cardiomyocytes at earlier time points in the differentiation.  Size was an important theme 
in this study, as beating was shown primarily in smaller aggregates and, in addition, later 
time points formed smaller aggregates.  Cardiospheres formed better before the 
differentiation process, groups 1 and 2 had larger aggregates that seemed to grow over 
time.  Groups 1 and 2 also had higher yields of aggregates.  Conversely, while the 
cardiospheres formed at later time points were smaller, they had a higher percentage of 
cardiomyocytes.  This could be because when forming cardiospheres after the small 
molecule directed differentiation, only the cells that had committed to the cardiac lineage 
bound together.  This would explain both the smaller aggregates formed and the higher 
percentage of cardiomyocytes in the cardiospheres.  This data will be analyzed through 
Flow Cytometry, PCR, and wholemount and replated 2D immunostaining with a-actinin. 
 This study implies additional cell-to-cell interactions related to cardiomyocyte 
efficiency.  Cardiosphere formation clearly affects cardiomyocyte purity and maturity, 
which is important for the clinical relevance of cardiomyocyte formation.  By increasing 
the maturity and purity of the cardiomyocyte yields, these differentiation protocols step 
closer to use for tissue engineering and cell based therapies. 
 
Limitations 
Unfortunately, the 2D differentiation shows a relatively low yield of 
cardiomyocytes compared to previous attempts.  This correlates to a lower yield of 
cardiomyocytes in the cardiospheres formed, which implies cardiosphere formation could 




 Since the cardiosphere size had the greatest effect on cardiomyocyte yield, future 
studies will be done with different seeding densities of cardiospheres.  Smaller 
cardiospheres could possibly help mature the cardiomyocytes faster, but there is a risk 
that the cardiospheres will be too small to withstand the small molecule directed 
differentiation treatment.  Forming cardiospheres at different time points had an 
unexpected affect on the resulting phenotypes of the cardiospheres.  Group 1 seemed to 
be large and dense, increasing in size throughout the protocol.  In addition, small dimples 
formed on a large number of the group 1 cardiospheres for unknown reasons.  Group 2, 
while also growing in size, were not as dense and seemed to undergo pinching, where 
smaller cardiospheres would break off from larger ones.  Further research needs to be 
done to understand these phenotypic differences and their possible implications for the 
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